Symbols / NMRD $0.00 +0.00% Nemaura Medical Inc.

Healthcare • Medical Devices • United States • PNK
NMRD Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
Exch · Country PNK · United States
Market Cap 8.07K
Enterprise Value 19.51M
Income -10.65M
Sales —
FCF (ttm) -10.07M
Book/sh -0.62
Cash/sh 0.01
Employees 36
Insider 10d —
IPO Dec 18, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S inf
P/B -0.00
P/C —
EV/EBITDA -1.73
EV/Sales —
Quick Ratio 0.02
Current Ratio 0.19
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.78
EPS next Y -0.44
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-02-12
Earnings (prior) 2024-02-12
ROA -81.19%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 40.35M
Shs Float 12.43M
Insider Own 0.00%
Instit Own 0.00%
Short Float 0.31%
Short Ratio 0.30
Short Interest 52.57K
52W High 0.00
vs 52W High -60.00%
52W Low 0.00
vs 52W Low 1,900.00%
Beta -116.46
Impl. Vol. —
Rel Volume 0.85
Avg Volume 585.00
Volume 500.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-4.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-21 main HC Wainwright & Co. Buy → Buy $3
2023-07-17 main EF Hutton Buy → Buy $4
2023-03-30 reit EF Hutton — → Buy $6
2023-02-28 main EF Hutton — → Buy $6
2023-02-27 main HC Wainwright & Co. — → Buy $7
2022-08-19 main HC Wainwright & Co. — → Buy $8
2022-03-29 init HC Wainwright & Co. — → Buy $12
2021-12-02 init EF Hutton — → Buy $8
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-03-31 2022-03-31
Total Revenue
0.08
-84.71%
0.50
Operating Revenue
0.08
-84.71%
0.50
Cost Of Revenue
1.55
+351.19%
0.34
Reconciled Cost Of Revenue
1.55
+351.19%
0.34
Gross Profit
-1.48
-1025.02%
0.16
Operating Expense
7.14
-7.65%
7.73
Research And Development
1.54
-1.18%
1.56
Selling General And Administration
5.60
-9.28%
6.17
General And Administrative Expense
5.60
-9.28%
6.17
Other Gand A
5.60
-9.28%
6.17
Total Expenses
8.69
+7.65%
8.07
Operating Income
-8.62
-13.80%
-7.57
Total Operating Income As Reported
-9.60
-26.75%
-7.57
EBITDA
-7.29
+0.73%
-7.34
Normalized EBITDA
-8.17
-11.31%
-7.34
Reconciled Depreciation
0.44
+93.28%
0.23
EBIT
-7.73
-2.12%
-7.57
Total Unusual Items
0.88
0.00
Total Unusual Items Excluding Goodwill
0.88
0.00
Special Income Charges
-0.98
0.00
Impairment Of Capital Assets
0.98
0.00
Net Income
-14.14
-1.85%
-13.89
Pretax Income
-14.14
+0.66%
-14.24
Net Non Operating Interest Income Expense
-6.41
+3.81%
-6.67
Interest Expense Non Operating
6.41
-3.81%
6.67
Net Interest Income
-6.41
+3.81%
-6.67
Interest Expense
6.41
-3.81%
6.67
Other Income Expense
0.88
—
Gain On Sale Of Security
1.86
—
Tax Provision
0.00
+100.00%
-0.35
Tax Rate For Calcs
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-14.14
-1.85%
-13.89
Net Income From Continuing Operation Net Minority Interest
-14.14
-1.85%
-13.89
Net Income From Continuing And Discontinued Operation
-14.14
-1.85%
-13.89
Net Income Continuous Operations
-14.14
-1.85%
-13.89
Normalized Income
-15.03
-8.22%
-13.89
Net Income Common Stockholders
-14.14
-1.85%
-13.89
Diluted EPS
-0.57
+3.39%
-0.59
Basic EPS
-0.57
+3.39%
-0.59
Basic Average Shares
24.88
+6.39%
23.38
Diluted Average Shares
24.88
+6.39%
23.38
Diluted NI Availto Com Stockholders
-14.14
-1.85%
-13.89
Line Item Trend 2023-03-31 2022-03-31
Total Assets
14.56
-34.11%
22.10
Current Assets
13.54
-32.61%
20.09
Cash Cash Equivalents And Short Term Investments
10.11
-43.07%
17.75
Cash And Cash Equivalents
10.11
-43.07%
17.75
Cash Financial
10.11
-43.07%
17.75
Receivables
0.41
+14.94%
0.36
Accounts Receivable
—
0.10
Taxes Receivable
0.41
+60.58%
0.26
Inventory
1.75
+17.95%
1.49
Raw Materials
1.59
+7.07%
1.48
Finished Goods
0.17
+2785.41%
0.01
Prepaid Assets
0.91
0.00
Other Current Assets
0.36
-27.70%
0.50
Total Non Current Assets
1.03
-49.04%
2.01
Net PPE
0.64
+20.54%
0.53
Gross PPE
1.11
+38.13%
0.81
Accumulated Depreciation
-0.47
-72.36%
-0.27
Machinery Furniture Equipment
1.11
+38.13%
0.81
Goodwill And Other Intangible Assets
0.38
-74.07%
1.48
Other Intangible Assets
0.38
-74.07%
1.48
Total Liabilities Net Minority Interest
26.38
+21.92%
21.64
Current Liabilities
22.27
+8.19%
20.58
Payables And Accrued Expenses
1.38
+98.36%
0.69
Payables
1.25
+815.14%
0.14
Accounts Payable
0.33
+139.63%
0.14
Current Accrued Expenses
0.13
-76.60%
0.56
Current Debt And Capital Lease Obligation
16.94
-11.71%
19.19
Current Debt
16.94
-11.71%
19.19
Other Current Borrowings
16.94
-11.71%
19.19
Current Deferred Liabilities
0.12
-52.31%
0.26
Current Deferred Revenue
0.12
-52.31%
0.26
Other Current Liabilities
3.82
+768.64%
0.44
Total Non Current Liabilities Net Minority Interest
4.11
+290.28%
1.05
Long Term Debt And Capital Lease Obligation
3.09
—
Long Term Debt
3.09
—
Non Current Deferred Liabilities
1.02
-2.96%
1.05
Non Current Deferred Revenue
1.02
-2.96%
1.05
Stockholders Equity
-11.81
-2634.78%
0.47
Common Stock Equity
-11.81
-2634.78%
0.47
Capital Stock
0.03
+19.90%
0.02
Common Stock
0.03
+19.90%
0.02
Share Issued
28.90
+19.90%
24.10
Ordinary Shares Number
28.90
+19.90%
24.10
Additional Paid In Capital
40.99
+7.04%
38.30
Retained Earnings
-51.88
-37.49%
-37.73
Gains Losses Not Affecting Retained Earnings
-0.96
-684.24%
-0.12
Other Equity Adjustments
-0.96
-684.24%
-0.12
Total Equity Gross Minority Interest
-11.81
-2634.78%
0.47
Total Capitalization
-8.73
-1972.31%
0.47
Working Capital
-8.73
-1665.77%
-0.49
Invested Capital
8.22
-58.20%
19.65
Total Debt
20.03
+4.39%
19.19
Net Debt
9.93
+589.48%
1.44
Net Tangible Assets
-12.20
-1101.93%
-1.01
Tangible Book Value
-12.20
-1101.93%
-1.01
Duefrom Related Parties Current
0.00
-100.00%
0.10
Dueto Related Parties Current
0.92
0.00
Line Item Trend 2023-03-31 2022-03-31
Operating Cash Flow
-8.45
-29.95%
-6.50
Cash Flow From Continuing Operating Activities
-8.45
-29.95%
-6.50
Net Income From Continuing Operations
-14.14
-1.85%
-13.89
Depreciation Amortization Depletion
0.44
+93.28%
0.23
Depreciation And Amortization
0.44
+93.28%
0.23
Other Non Cash Items
6.42
-3.75%
6.67
Stock Based Compensation
0.00
-100.00%
0.22
Asset Impairment Charge
2.46
0.00
Operating Gains Losses
-1.57
-457.22%
0.44
Gain Loss On Investment Securities
-1.57
-457.22%
0.44
Change In Working Capital
-2.05
-1075.35%
-0.17
Change In Receivables
1.02
+508.68%
-0.25
Change In Inventory
-1.75
-173.91%
-0.64
Change In Prepaid Assets
-0.02
-103.35%
0.52
Change In Payables And Accrued Expense
-0.24
-222.95%
0.19
Change In Accrued Expense
-0.43
-237.77%
0.31
Change In Payable
0.19
+262.14%
-0.12
Change In Account Payable
0.19
+262.14%
-0.12
Change In Other Working Capital
-1.08
—
Change In Other Current Liabilities
—
0.31
Investing Cash Flow
-0.54
+43.62%
-0.96
Cash Flow From Continuing Investing Activities
-0.54
+43.62%
-0.96
Net PPE Purchase And Sale
-0.38
+21.91%
-0.48
Purchase Of PPE
-0.38
+21.91%
-0.48
Capital Expenditure
-0.54
+43.62%
-0.96
Capital Expenditure Reported
-0.14
-61.51%
-0.08
Net Intangibles Purchase And Sale
-0.03
+92.87%
-0.39
Purchase Of Intangibles
-0.03
+92.87%
-0.39
Financing Cash Flow
2.08
+132.69%
-6.37
Cash Flow From Continuing Financing Activities
2.08
+132.69%
-6.37
Net Issuance Payments Of Debt
-5.57
+55.05%
-12.40
Issuance Of Debt
4.70
0.00
Repayment Of Debt
-10.27
+17.14%
-12.40
Long Term Debt Issuance
4.70
0.00
Long Term Debt Payments
-10.27
+17.14%
-12.40
Net Long Term Debt Issuance
-5.57
+55.05%
-12.40
Net Common Stock Issuance
8.39
+169.14%
3.12
Proceeds From Stock Option Exercised
0.00
-100.00%
2.96
Net Other Financing Charges
-0.74
-1353.08%
-0.05
Changes In Cash
-6.91
+50.04%
-13.83
Effect Of Exchange Rate Changes
-0.74
-155.91%
-0.29
Beginning Cash Position
17.75
-44.30%
31.87
End Cash Position
10.11
-43.07%
17.75
Free Cash Flow
-8.99
-20.51%
-7.46
Interest Paid Supplemental Data
0.00
0.00
Common Stock Issuance
8.39
+169.14%
3.12
Issuance Of Capital Stock
8.39
+169.14%
3.12
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category